Phases, evaluation and treatment of acute renal tubular necrosis

INTRODUCTION

Acute renal tubular necrosis (ATN) is a severe form of kidney injury characterized by the death of renal tubular cells, resulting in impaired kidney function.¹ It is a critical medical condition that can arise from various etiologies, including ischemic injury, nephrotoxic agents, and sepsis.² ATN is associated with high morbidity and mortality rates, making it a significant concern in clinical practice and research.

The pathophysiology of ATN involves a complex interplay of hemodynamic alterations, inflammatory processes, and cellular dysfunction. Ischemic ATN occurs when there is an insufficient blood supply to the kidneys, leading to tissue hypoxia and subsequent tubular cell death.³ This can result from conditions such as severe hypotension, renal artery stenosis, or renal vascular thrombosis.⁴ On the other hand, nephrotoxic ATN is induced by the direct toxic effects of certain substances on the renal tubular cells. Common nephrotoxic agents include aminoglycoside antibiotics, contrast agents, nonsteroidal anti-inflammatory drugs (NSAIDs), and certain chemotherapeutic agents.⁵ The initial insult in ATN triggers a cascade of events that contribute to renal injury. Prolonged ischemia or exposure to nephrotoxic agents leads to the disruption of cellular energy production, oxidative stress, and impaired mitochondrial function.⁶ Consequently, renal tubular epithelial cells undergo apoptosis or necrosis, causing tubular obstruction and dysfunction. The damage to the tubular epithelium results in the loss of the kidneys' ability to concentrate urine, reabsorb electrolytes, and eliminate waste products effectively.

Clinical manifestations of ATN often include a decline in urine output, electrolyte imbalances (such as hyperkalemia and metabolic acidosis), and fluid overload.⁷ The severity of these symptoms varies depending on the extent and duration of renal the injury. Laboratory investigations reveal elevated levels of blood urea nitrogen (BUN) and serum creatinine, indicating impaired kidney function.⁸ Additionally, urinalysis may show the presence of tubular epithelial cells and granular casts, which are indicative of tubular damage.⁹

The management of ATN involves addressing the underlying cause, supportive care, and preventing complications. Identifying and treating the precipitating factors, such as hypovolemia, sepsis, or drug toxicity, is crucial to halting the progression of renal injury. Patients with ATN often require careful fluid management to maintain adequate renal perfusion while avoiding fluid overload.¹⁰ Electrolyte imbalances should be corrected promptly, and renal replacement therapy, such as hemodialysis or continuous renal replacement therapy, may be necessary in severe cases.

Preventing ATN requires a multidisciplinary approach emphasizing measures to minimize the risk of ischemic or nephrotoxic insults.¹¹ Adequate hydration, avoiding nephrotoxic drugs when possible, and optimizing hemodynamic stability are key strategies in preventing ATN. In critically ill patients, close monitoring of renal function and early detection of ATN are vital for timely intervention.

LITERATURE SEARCH

This study is based on a comprehensive literature search conducted on July 6, 2023, in the Medline and Cochrane databases, utilizing the medical topic headings (MeSH) and a combination of all available related terms, according to the database. To prevent missing any possible research, a manual search for publications was conducted through Google Scholar, using the reference lists of the previously listed papers as a starting point. We looked for valuable information in papers that discussed the phases, evaluation, and treatment of ATN. There were no restrictions on date, language, participant age, or type of publication.

DISCUSSION

The progression of ATN can be divided into distinct phases, each marked by specific pathophysiological changes and clinical manifestations.¹² Understanding these phases is essential for accurate diagnosis, effective management, and improved patient outcomes.

The initiation phase of ATN is characterized by the initial insult to the renal tubular cells, which triggers a cascade of events leading to cellular injury and death.¹³ The two main etiologies of ATN, ischemic and nephrotoxic, exhibit different mechanisms in this phase. Ischemic ATN occurs when the renal blood flow is compromised, resulting in tissue hypoxia and reduced oxygen delivery to the renal tubules.¹⁴ This can be caused by conditions such as hypotension, renal artery stenosis, or renal vascular thrombosis. Nephrotoxic ATN, on the other hand, arises from the direct toxic effects of substances on the tubular cells, such as aminoglycoside antibiotics, contrast agents, or certain chemotherapeutic drugs.¹⁵ In both cases, the insult disrupts cellular energy production, leading to cellular dysfunction, oxidative stress, and ultimately cell death.

Following the initiation phase, the maintenance phase of ATN ensues. This phase is characterized by sustained renal injury and the persistence of tubular cell death.¹¹ The primary pathophysiological feature of the maintenance phase is the formation of intraluminal casts composed of cellular debris and proteins within the renal tubules. These casts obstruct the tubular lumens, impairing tubular flow and compromising renal function. Consequently, the kidneys' ability to reabsorb electrolytes, concentrate urine, and eliminate waste products is severely compromised. Clinically, patients in the maintenance phase often present with oliguria or anuria, indicating reduced urine output.⁷ They may also exhibit electrolyte imbalances, such as hyperkalemia and metabolic acidosis, due to impaired renal function.

The recovery phase of ATN follows the maintenance phase and is characterized by the restoration of renal function and tubular integrity.¹⁶ During this phase, the damaged tubular cells undergo repair and regeneration, leading to the clearance of intraluminal casts and the restoration of normal tubular function. The recovery of renal function is typically accompanied by an increase in urine output, indicating improved tubular flow. Laboratory markers, such as blood urea nitrogen (BUN) and serum creatinine levels, also show a gradual decline as renal function improves.¹⁷ However, it is important to note that the recovery phase can be variable and may not occur uniformly for all patients. Some individuals may experience incomplete recovery or residual renal dysfunction, necessitating ongoing monitoring and management.

The phases of ATN represent a dynamic process with distinct pathophysiological changes and clinical manifestations. The initiation phase involves the initial insult and the subsequent cellular injury, while the maintenance phase is characterized by sustained tubular cell death and intraluminal cast formation. The recovery phase signifies the restoration of renal function and the resolution of tubular damage. By understanding the progression of ATN through these phases, healthcare providers can tailor their diagnostic and therapeutic approaches, accordingly, optimizing patient care and outcomes.

The evaluation of ATN involves a comprehensive approach aimed at confirming the diagnosis, identifying the underlying cause, assessing the severity of renal injury, and guiding appropriate management strategies.¹ This process entails a combination of clinical assessment, laboratory investigations, and imaging modalities to establish a precise and timely evaluation of ATN.

Clinical evaluation serves as the initial step in assessing patients suspected of having ATN. A thorough medical history is obtained, focusing on potential risk factors for renal injury, such as recent exposure to nephrotoxic agents, hypovolemia, sepsis, or underlying systemic diseases.⁴ Attention is given to signs and symptoms, including changes in urine output, fluid overload, electrolyte imbalances, and the presence of predisposing conditions. Physical examination findings, such as edema, hypertension, and clinical evidence of the underlying etiology, are carefully assessed.¹⁸

Laboratory investigations play a crucial role in the evaluation of ATN. Renal function tests, including serum creatinine and blood urea nitrogen (BUN) levels, provide essential information on the severity and progression of renal injury.¹⁹ Elevated levels of these markers are indicative of impaired kidney function. Additionally, a comprehensive metabolic panel is often performed to assess electrolyte imbalances, acid-base disturbances, and other renal-related abnormalities. Urinalysis helps to identify characteristic findings associated with ATN, including the presence of tubular epithelial cells, granular casts, and proteinuria.²⁰

Imaging modalities are utilized to aid in the evaluation of ATN. Renal ultrasound is often the initial imaging modality of choice due to its widespread availability, non-invasive nature, and ability to provide valuable information. Ultrasound findings in ATN may reveal enlarged kidneys, loss of corticomedullary differentiation, and increased echogenicity, suggesting parenchymal injury.²¹ Doppler ultrasound can assess renal blood flow and exclude obstructive uropathy as a potential cause of renal dysfunction.²² In certain cases, advanced imaging techniques such as computed tomography (CT) or magnetic resonance imaging (MRI) may be employed to evaluate specific etiologies or complications associated with ATN.²³ These modalities can provide detailed anatomical information, identify vascular abnormalities, assess renal perfusion, and detect any underlying structural abnormalities that may contribute to renal injury.

Further diagnostic evaluations may be necessary in specific situations to identify the underlying cause of ATN. This may involve serological tests to assess for autoimmune disorders or infectious diseases, renal biopsy for histological evaluation in cases of diagnostic uncertainty or suspected alternative diagnoses, or additional imaging studies such as renal scintigraphy or angiography for specialized indications.²⁴ The evaluation of ATN is a comprehensive and multidimensional process involving clinical assessment, laboratory investigations, and imaging modalities. It requires careful consideration of the patient's medical history, physical examination findings, and the judicious use of diagnostic tools to confirm the diagnosis, identify the underlying cause, assess the severity of renal injury, and guide appropriate management strategies. By employing a systematic and evidence-based approach, healthcare providers can optimize patient care, facilitate timely interventions, and improve outcomes for individuals with ATN.

The management of ATN requires a multifaceted approach that aims to address the underlying cause, provide supportive care, and prevent complications. Effective management strategies encompass pharmacological interventions, fluid management, electrolyte balance, and, in severe cases, renal replacement therapy.¹⁹ Additionally, close monitoring, patient education, and preventive measures are crucial components of ATN management. The initial step in managing ATN involves identifying and addressing the underlying cause of renal injury. This may include discontinuing or adjusting doses of nephrotoxic medications, addressing hypovolemia through fluid resuscitation, treating sepsis, or managing any other precipitating factors.²⁵ By addressing the cause, it is possible to halt or minimize further renal injury and potentially initiate the recovery process.

Fluid management plays a critical role in the management of ATN.¹⁴ Adequate hydration is necessary to maintain renal perfusion, prevent hypovolemia, and optimize renal function. However, careful attention must be paid to avoid fluid overload, which can exacerbate pulmonary edema and other complications.²⁶ Close monitoring of fluid balance, including urine output, vital signs, and central venous pressure, is essential to guiding appropriate fluid administration.²⁷ Electrolyte imbalances are common in ATN and require vigilant management. Hyperkalemia, resulting from impaired renal potassium excretion, poses a significant risk and may necessitate interventions such as dietary modification, administration of potassium-binding agents/ use of pharmacological agents that promote potassium elimination (e.g., loop diuretics).²⁸ Similarly, acid-base imbalances, such as metabolic acidosis, should be corrected using bicarbonate supplementation or appropriate ventilation strategies.²⁹ In severe cases of ATN with refractory metabolic acidosis, electrolyte imbalances, or fluid overload, renal replacement therapy (RRT) may be required.³⁰ RRT modalities, including intermittent hemodialysis, continuous renal replacement therapy (CRRT)/peritoneal dialysis, effectively support renal function by removing waste products, maintaining electrolyte balance, and controlling fluid status.³¹ The choice of RRT modality is determined based on the patient's clinical status, hemodynamic stability, and the availability of resources. Close monitoring of renal function and associated parameters is essential in managing ATN. Serial measurements of serum creatinine, blood urea nitrogen (BUN), and urine output provide valuable information about the progression and recovery of renal injury.³² Additionally, regular assessment of electrolytes, acid-base balance, and fluid status is necessary to guide appropriate interventions and prevent complications.

Patient education is a vital component of ATN management. Providing information about the condition, its underlying causes, and the importance of adherence to therapeutic interventions can empower patients to actively participate in their care.³³ Education regarding medication adherence, fluid restrictions (if applicable), and the recognition of signs and symptoms of potential complications is essential to ensuring optimal management outcomes.

Preventive measures are also crucial in management of ATN.¹ Identifying patients at high risk for renal injury, such as those with pre-existing renal dysfunction/ undergoing procedures associated with nephrotoxicity, allows for targeted interventions to minimize likelihood of ATN development. Implementing strategies to optimize renal perfusion, avoid nephrotoxic agents whenever possible and closely monitor renal function during high risk situations are essential preventive measures.³⁴

CONCLUSION

In conclusion, the management of ATN is a complex and multifaceted process that requires a thorough evaluation, an accurate diagnosis, and targeted interventions. Understanding of the phases of ATN, including initiation, maintenance, and recovery, is crucial in guiding appropriate management strategies. Prompt identification and management of the underlying cause, supportive care, fluid and electrolyte management, and, in severe cases, renal replacement therapy are essential components of ATN management. Furthermore, close monitoring, patient education, and preventive measures play a vital role in optimizing patient outcomes and preventing complications. Continued research and advancements in diagnostic modalities, therapeutic interventions, and preventive strategies are necessary to improve the management and prognosis of ATN. Through a comprehensive and multidisciplinary approach, healthcare providers can enhance patient care, alleviate the burden of ATN, and strive for better outcomes for affected individuals.

Funding: No funding sources

Conflict of interest: None declared

Ethical approval: Not required

REFERENCES

1. 1. Hanif MO, Bali A, Ramphul K. Acute renal tubular necrosis. In: StatPearls. StatPearls Publishing. 2022.
2. 2. Santos WJ, Zanetta DM, Pires AC, Lobo S, Lima EQ, Burdmann EA. Patients with ischaemic, mixed and nephrotoxic acute tubular necrosis in the intensive care unit–a homogeneous population? Critical Care. 2006;10(2):1-9.
3. 3. Rosen S, Stillman IE. Acute tubular necrosis is a syndrome of physiologic and pathologic dissociation. J Am Society Nephrol. 2008;19(5):871-5.
4. 4. Mercado MG, Smith DK, Guard EL. Acute kidney injury: diagnosis and management. Am Family Physician. 2019;100(11):687-94.
5. 5. Nolin TD, Himmelfarb J. Mechanisms of drug-induced nephrotoxicity. Adverse Drug React. 2010:111-30.
6. 6. Linkermann A, De Zen F, Weinberg J, Kunzendorf U, Krautwald S. Programmed necrosis in acute kidney injury. Nephrology Dialysis Transplantation. 2012;27(9):3412-9.
7. 7. Rahman M, Shad F, Smith MC. Acute kidney injury: a guide to diagnosis and management. American family physician. 2012;86(7):631-9.
8. 8. Kamal A. Estimation of blood urea (BUN) and serum creatinine level in patients of renal disorder. Indian J Fundam Appl Life Sci. 2014;4(4):199-202.
9. 9. Kanbay M, Kasapoglu B, Perazella MA. Acute tubular necrosis and pre-renal acute kidney injury: utility of urine microscopy in their evaluation-a systematic review. Int Urol Nephrol. 2010;42:425-33.
10. 10. Prowle JR, Kirwan CJ, Bellomo R. Fluid management for the prevention and attenuation of acute kidney injury. Nature Rev Nephrol. 2014;10(1):37-47.
11. 11. Lameire N, Vanholder R. Pathophysiologic features and prevention of human and experimental acute tubular necrosis. J Am Society Nephrol. 2001;12(1):S20-32.
12. 12. Kundert F, Platen L, Iwakura T, Zhao Z, Marschner JA, Anders H-J. Immune mechanisms in the different phases of acute tubular necrosis. Kidney Res Clin Pract. 2018;37(3):185.
13. 13. Turner JM, Coca SG. Acute tubular injury and acute tubular necrosis. In: National Kidney Foundation Primer on Kidney Diseases. Elsevier; 2018:311-9.
14. 14. Heyman SN, Lieberthal W, Rogiers P, Bonventre JV. Animal models of acute tubular necrosis. Curr Opinion Critical Care. 2002;8(6):526-34.
15. 15. Bhandare PA, Gadekar GJ, Bandawane DD. Drug Induced Nephrotoxicity: A Mechanistic Approach. 2020.
16. 16. Dunnill M. A review of the pathology and pathogenesis of acute renal failure due to acute tubular necrosis. J Clin Pathol. 1974;27(1):2.
17. 17. Doi K, Katagiri D, Negishi K, et al. Mild elevation of urinary biomarkers in prerenal acute kidney injury. Kidney Int. 2012;82(10):1114-20.
18. 18. Okusa MD. Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury in adults. 2019.
19. 19. Esson ML, Schrier RW. Diagnosis and treatment of acute tubular necrosis. Ann Int Med. 2002;137(9):744-52.
20. 20. West BL, Picken MM, Leehey DJ. Albuminuria in acute tubular necrosis. Nephrol Dialysis Transplantation. 2006;21(10):2953-6.
21. 21. Barozzi L, Valentino M, Santoro A, Mancini E, Pavlica P. Renal ultrasonography in critically ill patients. Critical Care Med. 2007;35(5):S198-205.
22. 22. Tranquart F, Lebranchu Y, Haillot O, Pourcelot D, Grezard O, Pourcelot L. The use of perioperative Doppler ultrasound as a screening test for acute tubular necrosis. Transplant Int. 1993;6(1):14-7.
23. 23. Kalantarinia K. Novel imaging techniques in acute kidney injury. Curr Drug Targ. 2009;10(12):1184-9.
24. 24. Albright Jr RC. Acute renal failure: a practical update. Paper presented at: Mayo Clinic Proceedings. 2001.
25. 25. Kellum JA, Romagnani P, Ashuntantang G, Ronco C, Zarbock A, Anders H-J. Acute kidney injury. Nature reviews Disease primers. 2021;7(1):52.
26. 26. Heung M, Wolfgram DF, Kommareddi M, Hu Y, Song PX, Ojo AO. Fluid overload at initiation of renal replacement therapy is associated with lack of renal recovery in patients with acute kidney injury. Nephrol Dialysis Transplantation. 2012;27(3):956-61.
27. 27. Song J, Wu W, He Y, Lin S, Zhu D, Zhong M. Value of the combination of renal resistance index and central venous pressure in the early prediction of sepsis-induced acute kidney injury. Journal of critical care. 2018;45:204-8.
28. 28. Batlle D, Arruda J. Hyperkalemic forms of renal tubular acidosis: clinical and pathophysiological aspects. Advances in Chronic Kidney Dis. 2018;25(4):321-33.
29. 29. Rodriguez-Soriano J. The renal regulation of acid-base balance and the disturbances noted in renal tubular acidosis. Pediatr Clin N Am. 1971;18(2):529-45.
30. 30. Gunnerson K. Emergency department management of acute kidney injury, electrolyte abnormalities, and renal replacement therapy in the critically ill. Emergency Med Clin. 2019;37(3):459-71.
31. 31. Murray P, Hall J. Renal replacement therapy for acute renal failure. Am J Respiratory Crit Care Med. 2000;162(3):777-81.
32. 32. Lisowska-Myjak B. Serum and urinary biomarkers of acute kidney injury. Blood Purification. 2010;29(4):357-65.
33. 33. Sancho-Martínez SM, Prieto L, Blanco-Gozalo V. Acute tubular necrosis: An old term in search for a new meaning within the evolving concept of acute kidney injury. New Horizons Translational Med. 2015;2(4-5):110-17.
34. 34. Harty J. Prevention and management of acute kidney injury. Ulster Med J. 2014;83(3):149.